Enliven Therapeutics (NASDAQ:ELVN) CFO Benjamin Hohl Sells 6,018 Shares of Company Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction on Monday, October 19th. The stock was sold at an average price of $38.48, for a total transaction of $231,572.64. Following the sale, the chief financial officer owned 38,000 shares in the company, valued at $1,462,240. This represents a 13.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Thursday, September 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $50.35, for a total transaction of $303,006.30.
• On Monday, August 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $58.58, for a total transaction of $352,534.44.

Enliven Therapeutics Stock Performance

Shares of ELVN stock traded up $0.57 during mid-day trading on Wednesday, reaching $41.82. The company’s stock had a trading volume of 2,052,540 shares, compared to its average volume of 1,270,769. The firm’s 50-day moving average is $51.25 and its two-hundred day moving average is $47.98. The company has a market cap of $3.06 billion, a P/E ratio of -25.04 and a beta of 0.24. Enliven Therapeutics, Inc. has a 1-year low of $14.78 and a 1-year high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.81 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ELVN. Guggenheim reiterated a “buy” rating on shares of Enliven Therapeutics in a research note on Thursday, October 8th. Mizuho increased their price target on Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. William Blair started coverage on Enliven Therapeutics in a research report on Tuesday, August 18th. They set an “outperform” rating on the stock. The Goldman Sachs Group raised their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, HC Wainwright raised their price target on Enliven Therapeutics from $65.00 to $73.00 and gave the company a “buy” rating in a report on Monday. Ten research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $75.44.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV acquired a new stake in shares of Enliven Therapeutics in the 1st quarter valued at $38,000. State of Wyoming bought a new stake in shares of Enliven Therapeutics during the second quarter worth $96,000. FNY Investment Advisers LLC acquired a new position in shares of Enliven Therapeutics during the second quarter valued at $126,000. WINTON GROUP Ltd acquired a new position in shares of Enliven Therapeutics during the second quarter valued at $228,000. Finally, Squarepoint Ops LLC bought a new position in Enliven Therapeutics in the second quarter valued at about $259,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Key Headlines Impacting Enliven Therapeutics

Here are the key news stories impacting Enliven Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy recommendation and $73 price objective for Enliven Therapeutics. The target indicates confidence in the company’s long-term pipeline and potential despite near-term losses.
• Neutral Sentiment: HC Wainwright estimates Enliven will report a $0.41 per-share loss in Q3 2026 and a $0.46 per-share loss in Q4 2026, resulting in a projected $1.74 loss per share for full-year 2026. The firm expects losses to continue through 2027, including $0.48 per share in Q1, $0.50 in Q2, $0.52 in Q3, and $0.55 in Q4.
• Negative Sentiment: The forecasts underscore that Enliven remains an unprofitable biotechnology company, with HC Wainwright projecting a $2.06-per-share loss for full-year 2027. Continued cash burn and the absence of near-term earnings could limit upside or increase sensitivity to clinical and financing developments.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.